Cargando…
Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review
It is unclear whether targeted agents can produce survival advantage in patients with advanced HCC previously treated with sorafenib. We performed this meta-analysis of randomized trials and reviewed clinical outcomes of molecular targeted agents in the second-line treatment for advanced HCC. A syst...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731957/ https://www.ncbi.nlm.nih.gov/pubmed/29254247 http://dx.doi.org/10.18632/oncotarget.21454 |